zika
viru
zikv
infect
remain
seriou
health
threat
due
close
associ
congenit
zika
syndrom
cz
includ
microcephali
sever
birth
defect
vaccin
avail
human
use
continu
effort
need
develop
effect
safe
vaccin
prevent
zikv
infect
studi
construct
three
recombin
protein
compris
respect
residu
zikv
envelop
e
protein
domain
iii
ediii
fuse
ctermin
fc
human
igg
result
demonstr
induc
highest
titer
neutral
antibodi
infect
nine
zikv
strain
isol
differ
host
countri
time
period
maintain
longterm
antizikv
immunogen
induc
neutral
antibodi
pup
born
mice
immun
fulli
protect
lethal
challeng
two
epidem
human
zikv
strain
flr
passiv
transfer
mous
sera
protect
pup
born
naiv
mice
well
type
interferon
receptordefici
adult
mice
lethal
challeng
human
zikv
strain
flr
protect
posit
correl
neutral
antibodi
data
suggest
critic
neutral
fragment
ie
fragment
induc
highli
potent
neutral
antibodi
diverg
zikv
strain
zikv
ediii
good
candid
develop
effect
safe
zikv
subunit
vaccin
protect
pregnant
mother
fetus
zikv
infect
antibodi
use
passiv
immun
prevent
zikv
infect
newborn
immunocompromis
adult
zika
viru
zikv
emerg
viral
pathogen
associ
sever
neurolog
diseas
includ
guillainbarr
syndrom
gb
congenit
zika
syndrom
cz
includ
microcephali
brain
abnorm
sever
birth
defect
increas
number
women
infect
zikv
pregnanc
given
birth
newborn
congenit
defect
lead
seriou
consequ
varieti
zikv
vaccin
base
inactiv
liveattenu
virus
viral
vector
dna
rna
viral
protein
develop
zikv
infect
experiment
anim
model
sever
progress
clinic
trial
date
howev
vaccin
avail
human
use
situat
call
continu
effort
develop
effect
safe
vaccin
zikv
infect
zikv
belong
flavivirida
famili
dengu
viru
denv
west
nile
viru
wnv
japanes
enceph
viru
jev
yellow
fever
viru
yfv
tickborn
encephalit
viru
tbev
fulllength
genom
zikv
encod
structur
protein
capsid
c
membran
precursor
membran
prm
envelop
e
addit
nonstructur
protein
among
e
protein
major
protein
induc
neutral
antibodi
zikv
infect
thu
main
target
develop
zikv
vaccin
zikv
e
protein
consist
domain
di
domain
ii
dii
domain
iii
diii
stalk
region
transmembran
domain
supplementari
figur
number
zikv
ebas
vaccin
develop
target
prme
fulllength
e
wherea
attempt
target
fragment
zikv
e
protein
domain
particularli
ediii
identifi
import
region
e
protein
develop
effect
safer
zikv
vaccin
although
zikv
e
protein
key
target
develop
zikv
vaccin
studi
found
antibodi
target
zikv
ediii
gener
crossreact
poorli
neutral
potent
enhanc
zikv
denv
infect
wherea
target
zikv
ediii
potent
neutral
activ
zikv
infect
addit
antibodi
target
denv
andor
wnv
e
protein
includ
fusion
loop
region
may
bind
crossreact
zikv
ediii
region
neutral
zikv
infect
thu
promot
antibodydepend
enhanc
ade
studi
construct
three
recombin
protein
compris
zikv
ediii
fragment
differ
length
found
one
zikv
ediii
fragment
could
induc
potent
neutral
antibodi
protect
newborn
mice
type
interferon
receptordefici
adult
mice
lethal
challeng
diverg
zikv
strain
present
studi
demonstr
identifi
ediii
fragment
develop
effect
safe
vaccin
prevent
zikv
infect
antibodi
use
preexposur
prophylaxi
zikv
infect
sevendayold
male
femal
balbc
pup
femal
balbc
mice
male
femal
mice
use
studi
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
protocol
approv
committe
ethic
anim
experi
new
york
blood
center
permit
number
recombin
zikv
ediii
fragment
prepar
previous
describ
modif
briefli
gene
encod
respect
zikv
ediii
fragment
amplifi
pcr
use
codonoptim
zikv
e
strain
genbank
access
plasmid
templat
follow
fusion
ctermin
fc
human
igg
hereinaft
recombin
zikv
e
residu
fuse
ctermin
fc
construct
describ
recombin
zikv
ediii
residu
contain
ctermin
foldon
sequenc
tag
ediiihi
construct
use
express
vector
aforement
plasmid
transfect
cell
respect
protein
harvest
cell
cultur
supernat
purifi
protein
affin
chromatographi
fctag
protein
ge
healthcar
port
washington
ny
usa
ninta
superflow
histag
protein
qiagen
germantown
md
usa
purifi
ediii
fragment
analyz
sdspage
western
blot
previous
describ
briefli
protein
boil
nonboil
separ
trisglycin
sdspage
gel
stain
coomassi
brilliant
blue
transfer
nitrocellulos
membran
western
blot
analysi
blot
block
fatfre
milk
pbst
overnight
incub
h
room
temperatur
zikv
ediiispecif
mous
monoclon
antibodi
mab
three
wash
blot
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
invitrogen
waltham
usa
h
room
temperatur
signal
detect
ecl
western
blot
substrat
buffer
amersham
hyperfilm
ge
healthcar
procedur
carri
previous
describ
briefli
femal
balbc
mice
intramuscularli
im
immun
ediii
protein
fragment
per
mous
pb
control
presenc
aluminum
alum
per
mous
monophosphoryl
lipid
mpla
per
mous
adjuv
invivogen
san
diego
ca
usa
boost
immunogen
day
day
month
month
respect
sera
collect
month
post
immun
test
antibodi
neutral
antibodi
mous
sera
analyz
zikv
ediiispecif
antibodi
respons
elisa
previous
describ
briefli
elisa
plate
coat
zikv
ediiihi
protein
overnight
block
fatfre
milk
h
serial
dilut
mous
sera
ad
plate
incub
h
wash
plate
incub
hrpconjug
antimous
igg
antimous
bethyl
laboratori
montgomeri
tx
usa
antimous
invitrogen
h
reaction
detect
tmb
substrat
invitrogen
stop
n
h
absorb
nm
measur
use
elisa
plate
reader
tecan
morrisvil
nc
usa
respect
antibodi
titer
calcul
amplifi
vero
cell
relat
viral
titer
determin
standard
plaqueform
assay
prnt
carri
measur
titer
neutral
antibodi
collect
mous
sera
briefli
viral
solut
zikv
plaqueform
unit
pfu
incub
serial
dilut
sera
eg
polyclon
antibodi
pab
neutral
mab
control
h
antibodyviru
mixtur
transfer
onto
vero
cell
incub
h
cell
overlaid
medium
carboxymethyl
cellulos
dmem
contain
fb
cultur
day
stain
crystal
violet
titer
neutral
antibodi
mous
sera
present
highest
dilut
sera
result
complet
inhibit
viru
infect
least
well
prnt
serum
test
duplic
well
fourfold
serial
dilut
neutral
activ
mab
calcul
duplic
well
serial
dilut
express
neutral
dose
nd
sevendayold
pup
born
femal
balbc
mice
vaccin
zikv
pb
respect
challeng
intraperiton
ip
pfu
zikv
flr
strain
solut
mous
surviv
weight
observ
day
postvir
infect
pi
passiv
protect
zikv
challeng
pup
born
naiv
femal
balbc
mice
mous
sera
immun
aforement
zikv
fragment
ip
inject
balbc
pup
per
pup
sera
dilut
pb
produc
log
elisa
titer
detect
igg
titer
use
zikv
ediiihi
protein
six
hour
later
pup
ip
challeng
pfu
zikv
flr
strain
describ
pup
inject
zikv
includ
sham
control
pup
also
receiv
anoth
dose
sera
h
postchalleng
viru
mous
surviv
weight
record
day
pi
fiveweekold
mice
ip
inject
sera
per
mous
zikv
ediiispecif
igg
titer
describ
mice
six
hour
later
mice
ip
challeng
pfu
zikv
flr
strain
mice
challeng
pfu
zikv
inject
sera
per
mous
h
h
pi
respect
mice
inject
zikv
includ
sham
control
mous
surviv
weight
evalu
day
pi
zikv
rna
titer
detect
sera
tissu
collect
day
pi
describ
patholog
chang
detect
tissu
collect
day
pi
h
e
stain
previous
describ
zikv
rna
copi
sera
tissu
challeng
mice
detect
qrtpcr
previous
describ
briefli
zikv
rna
extract
use
qiaamp
minelut
viru
spin
kit
sera
qiagen
rneasi
mini
kit
tissu
qiagen
extract
zikv
rna
quantifi
use
onestep
qrtpcr
power
sybr
green
pcr
master
mix
multiscrib
revers
transcriptas
ambion
rnase
inhibitor
thermo
fisher
scientif
waltham
usa
viia
master
cycler
pcr
system
thermo
fisher
scientif
accord
manufactur
instruct
forward
revers
primer
use
amplif
respect
valu
present
mean
standard
error
se
statist
signific
among
differ
group
calcul
student
twotail
ttest
use
graphpad
prism
statist
softwar
indic
p
p
p
respect
zikv
ediii
fragment
especi
induc
broadspectrum
neutral
antibodi
maintain
longterm
immunogen
three
zikv
ediii
fragment
compris
residu
respect
construct
fuse
ctermin
fc
supplementari
figur
except
cover
entir
sequenc
ediii
residu
residu
edi
stalk
region
supplementari
figur
recombin
protein
express
cell
cultur
supernat
purifi
high
puriti
form
dimer
structur
maintain
good
conform
supplementari
figur
particularli
ediii
fragment
recogn
mab
specif
zikv
ediii
protein
supplementari
figur
demonstr
strong
specif
zikv
evalu
immunogen
three
ediii
fragment
use
purifi
protein
immun
femal
balbc
mice
follow
immun
schedul
describ
supplementari
figur
sera
collect
month
immun
test
crossneutr
nine
zikv
strain
isol
differ
host
human
mosquito
rhesu
variou
countri
region
colombia
hondura
panama
puerto
rico
thailand
nigeria
mexico
uganda
differ
period
time
supplementari
figur
zikv
strain
belong
divers
phylogenet
group
supplementari
figur
number
amino
acid
variat
among
e
protein
supplementari
figur
compar
fragment
fragment
induc
higher
titer
neutral
antibodi
abl
crossneutr
zikv
strain
test
fig
includ
differ
ediii
sequenc
eg
isol
patient
american
countri
ibh
isol
patient
african
countri
mr
isol
rhesu
macaqu
african
countri
ediii
sequenc
eg
flr
mex
isol
patient
mosquito
american
countri
plcalzv
isol
patient
asian
countri
supplementari
figur
specif
level
neutral
antibodi
significantli
higher
induc
either
epidem
human
strain
flr
fig
fig
strain
plcalzv
fig
strain
ibh
fig
comparison
zikvspecif
neutral
antibodi
detect
control
mice
inject
pb
fig
result
demonstr
zikv
ediii
fragment
particularli
capabl
elicit
highli
potent
neutral
antibodi
diverg
human
mosquito
rhesu
zikv
strain
differ
countri
year
investig
longterm
immunogen
neutral
activ
zikv
ediii
fragment
immun
mice
observ
month
sera
collect
month
post
immun
test
zikv
ediii
especif
antibodi
respons
neutral
antibodi
two
select
epidem
human
strain
flr
data
antibodi
test
reveal
although
three
ediii
fragment
abl
elicit
longterm
ediiispecif
igg
antibodi
induc
fragment
show
significantli
higher
titer
induc
fragment
fig
igg
antibodi
test
use
zikv
e
protein
contain
residu
result
show
especif
igg
antibodi
correspond
respect
ediiispecif
igg
antibodi
induc
three
ediii
fragment
fig
compar
elicit
rel
higher
titer
ediiispecif
antibodi
fig
similar
level
antibodi
fig
induc
lowest
titer
antibodi
among
three
fragment
test
month
fig
elicit
potent
longterm
neutral
antibodi
respons
zikv
fig
flr
fig
strain
least
month
fig
contrast
control
pb
induc
background
level
igg
antibodi
respons
neutral
antibodi
two
test
zikv
strain
fig
data
indic
zikv
ediii
fragment
especi
maintain
immunogen
requir
elicit
longterm
ediii
especif
antibodi
respons
particularli
neutral
antibodi
respons
infect
variant
epidem
human
zikv
strain
zikv
ediii
fragment
protect
pup
born
immun
balbc
mice
challeng
diverg
epidem
human
zikv
strain
confirm
immunogen
zikv
ediii
fragment
next
want
know
whether
antibodi
induc
protein
could
protect
zikv
infect
anim
model
vivo
sevendayold
newborn
mice
pup
conveni
effect
mean
evalu
protect
efficaci
zikv
vaccin
highli
suscept
zikv
infect
therefor
initi
use
pup
born
immun
femal
balbc
mice
month
post
immun
zikv
challeng
supplementari
figur
theoret
pup
receiv
antizikv
neutral
antibodi
mother
pregnanc
expect
protect
zikv
infect
test
protect
efficaci
zikv
ediii
fragment
pup
challeng
pfu
aforement
two
epidem
human
zikv
strain
flr
result
surviv
weight
well
neutral
antibodi
mother
pup
evalu
except
pup
mice
immun
surviv
rate
zikv
challeng
pup
born
mice
surviv
challeng
fig
pup
born
mice
surviv
flr
challeng
fig
pup
born
three
ediii
fragmentimmun
mice
increas
weight
detect
period
day
challeng
fig
flr
fig
strain
evalu
neutral
antibodi
reveal
similar
immun
mother
pup
mice
highest
neutral
antibodi
titer
among
three
treatment
fig
flr
fig
strain
contrast
result
pup
born
mice
inject
pb
surviv
challeng
fig
flr
fig
strain
die
day
pi
respect
decreas
weight
day
postchalleng
fig
flr
fig
result
mainli
neutral
antibodi
detect
mother
inject
pb
fig
f
result
demonstr
pup
born
mice
immun
zikv
ediii
fragment
particularli
protect
infect
diverg
zikv
strain
possibl
matern
neutral
antibodi
transfer
via
placenta
mother
fetus
pregnanc
plcalzv
f
ibh
g
well
mosquito
mex
h
rhesu
mr
neutral
activ
express
neutral
antibodi
titer
prnt
data
present
mean
se
mice
group
n
signific
differ
note
two
ediii
fragment
flr
p
p
plcalzv
p
ibh
p
respect
experi
repeat
twice
similar
result
obtain
mous
sera
collect
immun
month
post
immun
zikv
ediii
fragment
pb
control
test
elisa
zikv
ediii
andor
e
b
specif
igg
c
antibodi
antibodi
titer
express
endpoint
dilut
remain
posit
detect
present
mean
se
mice
group
n
ediiispecif
igg
signific
differ
observ
month
p
month
p
post
immun
especif
igg
b
signific
differ
found
p
month
p
p
month
p
post
immun
signific
differ
note
p
p
month
post
immun
signific
differ
occur
month
p
p
month
post
immun
b
aforement
sera
test
prnt
assay
infect
zikv
flr
b
strain
neutral
antibodi
titer
express
prnt
present
mean
se
mice
group
n
signific
differ
occur
two
ediii
fragment
p
flr
p
respect
indic
month
post
immun
experi
repeat
twice
similar
result
obtain
adopt
transfer
zikv
mous
sera
complet
protect
naiv
pup
challeng
diverg
epidem
human
zikv
strain
elucid
mechan
zikv
ediii
fragment
protect
zikv
infect
understand
correl
neutral
antibodi
protect
pup
born
naiv
balbc
mice
passiv
transfer
sera
equal
zikv
ediiispecif
igg
titer
mice
immun
zikv
ediii
fragment
h
later
pup
challeng
pfu
zikv
flr
observ
surviv
weight
chang
pup
transfer
sera
higher
neutral
antibodi
titer
either
sera
zikv
fig
flr
fig
exhibit
highest
surviv
rate
among
three
group
challeng
zikv
strain
fig
expect
pup
receiv
sera
lowest
neutral
antibodi
titer
flr
fig
b
lowest
surviv
rate
among
three
group
challeng
flr
fig
clearli
pup
receiv
sera
mice
immun
three
ediii
fragment
abl
maintain
bodi
weight
challeng
zikv
strain
fig
f
contrast
pup
sham
control
surviv
zikv
challeng
pup
die
day
pi
respect
flr
strain
fig
continu
decreas
weight
day
postchalleng
zikv
strain
fig
f
one
dose
sera
could
fulli
protect
pup
zikv
infect
pup
given
addit
dose
sera
h
postchalleng
fig
adopt
transfer
zikv
ediiiimmun
mous
sera
protect
pup
born
balbc
mice
challeng
two
epidem
human
zikv
strain
group
pup
n
born
naiv
balbc
mice
adopt
transfer
sera
mice
immun
ediii
fragment
challeng
zikv
pfu
h
later
neutral
antibodi
titer
prnt
adopt
transfer
sera
zikv
flr
b
strain
treatment
shown
sera
adjust
equal
titer
igg
antibodi
specif
zikv
ediii
percentag
surviv
pup
challeng
zikv
c
flr
well
percentag
weight
pup
challeng
zikv
e
flr
f
record
day
pi
data
e
f
present
mean
se
surviv
pup
group
pup
infect
zikv
includ
sham
control
two
dose
cf
indic
pup
adopt
transfer
two
dose
sera
h
h
zikv
infect
zikv
interestingli
pup
complet
protect
flr
challeng
fig
weight
steadili
increas
observ
period
fig
f
data
confirm
protect
level
pup
zikv
infect
associ
amount
neutral
antibodi
induc
zikv
ediii
fragment
given
pup
born
mother
mice
immun
pup
receiv
sera
fulli
protect
zikv
infect
test
whether
sera
could
also
protect
fig
adopt
transfer
sera
mice
immun
zikv
ediii
protect
lethal
mice
challeng
two
epidem
human
zikv
strain
follow
three
experi
carri
mice
n
mice
infect
zikv
includ
sham
control
mice
passiv
transfer
sera
eg
zikv
ediiispecif
igg
antibodi
titer
challeng
zikv
pfu
h
later
percentag
surviv
weight
b
calcul
day
pi
mice
passiv
transfer
sera
h
h
infect
zikv
flr
c
e
f
pfu
strain
percentag
surviv
record
flr
c
e
well
weight
flr
f
day
pi
mice
passiv
transfer
sera
h
h
postchalleng
zikv
pfu
percentag
surviv
g
weight
h
record
day
pi
data
b
f
g
present
mean
se
surviv
mice
group
type
interferon
receptordefici
adult
mice
highli
suscept
zikv
infect
lethal
zikv
challeng
sera
equal
zikv
ediiispecif
igg
titer
neutral
antibodi
titer
respect
flr
infect
adopt
transfer
adult
mice
surviv
weight
chang
record
challeng
mice
three
differ
challeng
experi
perform
mice
first
mice
receiv
sera
h
infect
pfu
zikv
fig
b
second
mice
receiv
sera
h
h
infect
higher
titer
pfu
zikv
flr
fig
fig
f
third
mice
receiv
sera
h
h
infect
pfu
zikv
fig
h
result
first
experi
demonstr
sham
control
mice
surviv
zikv
challeng
pfu
show
increas
weight
loss
mice
receiv
neutral
sera
surviv
zikv
infect
fig
increas
weight
challeng
fig
result
suggest
antibodi
also
protect
immunocompromis
adult
mice
zikv
infect
data
second
experi
reveal
mice
passiv
transfer
sera
protect
challeng
higher
titer
pfu
zikv
flr
fig
fig
f
strain
result
third
experi
indic
increas
dose
passiv
transfer
sera
neutral
activ
enhanc
mous
surviv
fig
slightli
increas
weight
fig
challeng
second
third
experi
control
mice
receiv
pfu
zikv
flr
die
day
pi
fig
e
g
decreas
weight
fig
f
h
abil
sera
inhibit
zikv
replic
evalu
mice
qrtpcr
day
pi
detect
viral
titer
tissu
sera
h
e
stain
day
pi
evalu
patholog
chang
tissu
qrtpcr
result
demonstr
mice
receiv
sera
significantli
reduc
viral
titer
tissu
includ
brain
lung
liver
spleen
kidney
sera
challeng
zikv
flr
strain
compar
sham
control
mice
receiv
sera
fig
analysi
patholog
chang
reveal
control
mice
sever
brain
damag
enhanc
neuron
eosinophilia
neuron
necrosi
tcell
prolifer
focal
bleed
brain
tissu
fig
well
seriou
interstiti
inflamm
focal
bleed
epitheli
cell
degener
inflammatori
cell
infiltr
lung
tissu
fig
contrast
seratr
mice
demonstr
consider
allevi
tissu
damag
along
significantli
decreas
neuron
eosinophilia
tcell
prolifer
brain
tissu
fig
slight
interstiti
inflamm
epitheli
cell
degener
inflammatori
cell
infiltr
lung
tissu
fig
line
evid
confirm
protect
mice
zikv
challeng
posit
correl
amount
neutral
antibodi
suggest
protect
mediat
ediiispecif
neutral
antibodi
result
demonstr
protect
efficaci
identifi
ediii
fragment
diverg
human
epidem
zikv
strain
studi
explor
potenti
develop
effect
safe
zikv
ediiibas
vaccin
potent
neutral
activ
protect
efficaci
zikv
infect
compar
crossneutr
protect
three
recombin
vaccin
encod
zikv
ediii
fragment
differ
length
identifi
critic
neutral
fragment
contain
residu
ediii
eg
induc
highest
titer
crossneutr
antibodi
infect
nine
zikv
strain
differ
ediii
sequenc
isol
differ
host
region
time
period
identifi
fragment
highest
neutral
potenti
protect
efficaci
protect
newborn
lethal
adult
mice
two
epidem
human
strain
zikv
test
data
suggest
nand
ctermin
residu
zikv
ediii
import
role
induc
protect
neutral
antibodi
appropri
extens
ediii
residu
ntermin
di
region
ctermin
stalk
region
supplementari
figur
help
product
effect
neutral
antibodi
zikv
infect
previou
studi
identifi
sever
zikv
ediiispecif
mous
neutral
mab
found
similar
mab
maintain
highest
neutral
capac
lowest
nd
neutral
supplementari
figur
recent
human
zikv
strain
pab
also
highest
neutral
activ
viral
strain
fig
addit
ediiispecif
pab
mab
effect
neutral
epidem
human
zikv
strain
test
includ
flr
fig
supplementari
figur
suggest
broad
neutral
capac
zikv
ediiispecif
antibodi
infect
zikv
particularli
pandem
human
strain
number
variat
demonstr
differ
strain
zikv
test
includ
viral
e
protein
supplementari
figur
abil
identifi
critic
neutral
domain
ediii
eg
induc
crossneutr
protect
efficaci
benefici
provid
use
guidanc
develop
effect
vaccin
protect
current
futur
epidem
zikv
strain
zikv
infect
remain
seriou
health
threat
pregnant
women
due
abil
zikv
cross
placenta
infect
fetus
lead
sever
birth
defect
therefor
critic
import
develop
vaccin
potent
efficaci
protect
pregnant
women
well
fetus
newborn
zikv
infect
reduc
occurr
cz
particularli
microcephali
studi
evalu
abil
zikv
ediii
fragment
protect
zikv
infect
pup
born
immun
femal
mice
confirm
pup
born
mice
highli
potent
neutral
antibodi
respons
fulli
protect
lethal
zikv
challeng
fig
adopt
transfer
sera
mice
immun
zikv
ediii
significantli
allevi
viral
replic
patholog
effect
zikvinfect
mice
fiveweekold
mice
n
passiv
transfer
sera
eg
zikv
ediiispecif
igg
antibodi
titer
challeng
zikv
flr
pfu
strain
h
h
infect
detect
zikv
rna
qrtpcr
tissu
brain
lung
kidney
liver
spleen
sera
day
pi
data
present
mean
se
six
mice
group
experi
repeat
twice
similar
result
obtain
signific
differ
p
p
p
seen
sham
control
group
test
tissu
sera
b
fiveweekold
mice
passiv
transfer
sera
c
infect
zikv
detect
patholog
chang
day
pi
repres
imag
mous
brain
b
lung
c
tissu
shown
h
estain
tissu
section
observ
light
microscopi
magnif
sham
control
mice
infect
zikv
result
suggest
neutral
antibodi
fetus
transfer
via
placenta
immun
pregnant
mother
effect
protect
newborn
zikv
infect
thu
provid
evid
show
effect
immun
pregnant
women
ediiibas
vaccin
protect
fetus
newborn
zikv
infect
protect
efficaci
zikv
mainli
associ
neutral
antibodi
target
viral
e
protein
inde
present
studi
demonstr
passiv
transfer
zikv
ediiispecif
neutral
antibodi
could
protect
naiv
newborn
zikv
infect
particularli
adopt
transfer
neutral
mous
sera
specif
identifi
fragment
confer
newborn
complet
protect
lethal
challeng
two
epidem
human
zikv
strain
sera
neutral
activ
also
protect
infect
two
zikv
strain
type
interferon
receptordefici
adult
mice
significantli
prevent
viral
replic
increas
mous
surviv
result
suggest
neutral
antibodi
effect
protect
normal
newborn
babi
immunocompromis
adult
zikv
infect
protect
zikv
infect
posit
associ
amount
neutral
antibodi
overal
studi
identifi
critic
fragment
overlap
zikv
ediii
develop
effect
safe
zikv
vaccin
express
protein
contain
show
promis
develop
efficaci
safe
vaccin
prevent
zikv
infect
highrisk
popul
particularli
pregnant
women
fetus
neutral
antibodi
may
also
use
preexposur
prophylaxi
zikv
infect
newborn
babi
immunocompromis
adult
